Greg Basarab is Principal Research Officer and Associate Director at the University of Cape Town (UCT), Drug Discovery and Development Centre (H3D).
He is Head of drug metabolism and pharmacokinetics (DMPK) and pharmacology groups located at Groote Schuur Hospital, Head of Institute of Infectious Diseases and Molecular Medicine, and Head of Medicinal Chemistry groups within the UCT Chemistry Department. He lectures at the UCT Medical School on Drug Disposition and Pharmacology.
Greg worked in various aspects of antibacterial and antifungal infection research for over 30 years at AstraZeneca and Dupont. He was an Associate Director leading multiple discovery project teams for novel mode-of-action antibacterial drugs and was responsible for three drug candidates that have entered into human clinical trials including zoliflodacin, a treatment for gonorrhoea scheduled to begin Phase III trials in 2018.
At Dupont Greg led projects in three departments: Central Research & Development, Biochemicals, and Agricultural Products, working in the antifungal arena and in automated chemical synthesis.
Greg received his BSc in Chemistry from Pennsylvania State University and PhD in Chemistry, working in natural products total synthesis, from the Massachusetts Institute of Technology.
Greg is the primary inventor of two clinical candidates, the inventor of over 30 patent applications and the author of over 50 publications in peer-reviewed journals.